MarketCapExport financials
CVS Health Corporation (CVS)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
CVS Health Corporation Income Statement 2025-2006 | CVS
Brief overview of financial performance at CVS Health Corporation
This overview is based on financial performance over the past five years. According to figures from CVS Health Corporation, revenue changed from 269 billion dollars to 402 billion dollars over five years. The total change was +49.6%, with a CAGR of approximately 8.4%. Revenue advanced gradually over the five-year period.
Gross profit changed from 105 billion dollars to 181 billion dollars (+72.7%). Direct costs grew more slowly than revenue and improved the economics of sales. At the margin level, the figure shifted from 39% to 45%. The margin shift points to a more favorable sales-and-cost structure.
EBITDA was 18.4 billion dollars at the beginning and 9.3 billion dollars at the end of the period (−49.5%). EBITDA lagged revenue, showing weaker operating momentum. The EBITDA share of revenue changed from 6.8% to 2.3%. A lower EBITDA share weakens the quality of the result.
Net income changed from $7.2 billion to $1.8 billion (−75.4%). Lower net income weakens the overall financial picture.
Market capitalization changed from $91 billion to $95.8 billion (+5.3%). The market value rose well beyond the pace of financial improvement.
Overall conclusion
The results contain several connected negative signals. The financial profile benefits from sales growth and a stronger gross margin. The weaker side of the profile includes pressure on operating profitability, limited operating profitability and declining net profitability. Investors should continue to monitor margins, costs, and earnings quality.
Annual Income Statement CVS Health Corporation
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
95.8 B | 80.5 B | 97.2 B | 118 B | 140 B | 91 B | 90.7 B | 68.9 B | 81.8 B | 84.4 B | 108 B | 114 B | 82.3 B | 65.6 B | 56.1 B | 46.9 B | 43.9 B | 61.2 B | 51.2 B | - |
Shares |
1.27 B | 1.26 B | 1.28 B | 1.31 B | 1.32 B | 1.31 B | 1.3 B | 1.04 B | 1.02 B | 1.07 B | 1.12 B | 1.16 B | 1.22 B | 1.27 B | 1.34 B | 1.37 B | 1.43 B | 1.43 B | 1.33 B | - |
Historical Prices |
75.6 | 63.9 | 75.7 | 89.9 | 106 | 69.5 | 63.8 | 59.6 | 69.5 | 67.9 | 81.7 | 82 | 55.5 | 41.3 | 33.2 | 34.3 | 30.6 | 42.7 | 38.5 | 28.6 |
Net Income |
1.77 B | 4.61 B | 8.34 B | 4.31 B | 8 B | 7.18 B | 6.63 B | -594 M | 6.62 B | 5.32 B | 5.24 B | 4.64 B | 4.59 B | 3.88 B | 3.46 B | 1.03 B | 1.05 B | 3.2 B | 2.64 B | - |
Revenue |
402 B | 373 B | 358 B | 322 B | 292 B | 269 B | 257 B | 195 B | 185 B | 178 B | 153 B | 139 B | 127 B | 123 B | 107 B | 95.8 B | 98.2 B | 87.5 B | 76.3 B | - |
Cost of Revenue |
221 B | 206 B | 217 B | 197 B | 176 B | 164 B | 159 B | 156 B | 156 B | 149 B | 127 B | 114 B | 103 B | 101 B | 86.5 B | 75.6 B | 77.9 B | 69.2 B | 60.2 B | - |
Gross Profit |
181 B | 167 B | 141 B | 126 B | 116 B | 105 B | 45.5 B | 31.5 B | 28.5 B | 28.9 B | 26.5 B | 25.4 B | 23.8 B | 22.5 B | 20.6 B | 20.2 B | 20.4 B | 18.3 B | 16.1 B | - |
Operating Income |
4.66 B | 8.52 B | 13.7 B | 7.95 B | 13.3 B | 13.9 B | 12 B | 4.02 B | 9.54 B | 10.4 B | 9.48 B | 8.8 B | 8.04 B | 7.21 B | 6.33 B | 6.14 B | 6.42 B | 6.05 B | 4.79 B | - |
Interest Expense |
112 M | 99 M | 2.66 B | 2.29 B | 2.5 B | 2.91 B | 3.04 B | 2.62 B | 1.06 B | 1.08 B | 859 M | 615 M | 517 M | 561 M | 588 M | 539 M | 530 M | 530 M | -435 M | - |
EBITDA |
9.27 B | 13.1 B | 18.1 B | 12.2 B | 17.8 B | 18.4 B | 16.4 B | 12.9 B | 12 B | 12.8 B | 11.5 B | 10.7 B | 9.91 B | 8.98 B | 7.9 B | 7.61 B | 7.81 B | 7.32 B | 5.89 B | - |
Operating Expenses |
176 B | 158 B | 127 B | 118 B | 103 B | 90.8 B | 33.5 B | 21.4 B | 19 B | 18.5 B | 17.1 B | 16.6 B | 15.7 B | 15.3 B | 14.2 B | 14.1 B | 13.9 B | 12.2 B | 11.3 B | - |
General and Administrative Expenses |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | 14.2 B | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Income Statement CVS Health Corporation
| 2026-Q3 | 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | 2010-Q4 | 2010-Q3 | 2010-Q2 | 2010-Q1 | 2009-Q4 | 2009-Q3 | 2009-Q2 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
1.28 B | 1.28 B | 1.27 B | 1 B | 1.27 B | 1.27 B | 1.26 B | 1 B | 1.26 B | 1.26 B | 1.26 B | 1 B | 1.29 B | 1.28 B | 1.28 B | -1 M | 1.32 B | 1.31 B | 1.31 B | 1 B | 1.32 B | 1.32 B | 1.31 B | 1 B | 1.31 B | 1.31 B | 1.31 B | 1 B | 1.3 B | 1.3 B | 1.3 B | 26 M | 1.02 B | 1.02 B | 1.02 B | -2 M | 1.02 B | 1.02 B | 1.03 B | 1.06 B | 1.07 B | 1.07 B | 1.09 B | 1.1 B | 1.11 B | 1.12 B | 1.13 B | 1.14 B | 1.16 B | 1.16 B | 1.18 B | 1.18 B | 1.22 B | 1.23 B | 1.23 B | 1.23 B | 1.26 B | 1.28 B | 1.3 B | 1.3 B | 1.33 B | 1.36 B | 1.36 B | - | 1.36 B | 1.36 B | 1.39 B | -11 M | 1.43 B | 1.46 B |
Net Income |
2.17 B | 2.98 B | 2.94 B | 2.94 B | -3.98 B | 1.02 B | 1.78 B | 1.64 B | 87 M | 1.77 B | 1.11 B | 2.05 B | 2.26 B | 1.9 B | 2.14 B | 2.33 B | -3.41 B | 3.03 B | 2.35 B | 1.4 B | 1.6 B | 2.78 B | 2.22 B | 986 M | 1.22 B | 2.98 B | 2.01 B | 1.75 B | 1.53 B | 1.94 B | 1.42 B | -419 M | 1.39 B | -2.56 B | 998 M | 3.29 B | 1.28 B | 1.1 B | 953 M | 1.71 B | 1.54 B | 924 M | 1.15 B | 1.5 B | 1.25 B | 1.27 B | 1.22 B | 1.32 B | 948 M | 1.25 B | 1.13 B | 1.26 B | 1.25 B | 1.12 B | 954 M | 1.12 B | 1 B | 961 M | 771 M | 1.06 B | 867 M | 816 M | 713 M | 1.03 B | 809 M | 821 M | 771 M | 1.05 B | 1.02 B | 886 M |
Revenue |
108 B | 106 B | 100 B | 106 B | 103 B | 98.9 B | 94.6 B | 97.7 B | 95.4 B | 91.2 B | 88.4 B | 93.8 B | 89.8 B | 88.9 B | 85.3 B | 83.8 B | 81.2 B | 80.6 B | 76.8 B | 76.6 B | 73.8 B | 72.6 B | 69.1 B | 69.6 B | 67.1 B | 65.3 B | 66.8 B | 66.9 B | 64.5 B | 63.1 B | 61.4 B | 54.4 B | 47.3 B | 46.7 B | 45.7 B | 48.4 B | 46.2 B | 45.7 B | 44.5 B | 46 B | 44.6 B | 43.7 B | 43.2 B | 41.1 B | 38.6 B | 37.2 B | 36.3 B | 37.1 B | 35 B | 34.6 B | 32.7 B | 32.8 B | 31.9 B | 31.2 B | 30.8 B | 31.4 B | 30.2 B | 30.7 B | 30.8 B | 28.3 B | 26.7 B | 26.4 B | 25.7 B | 24.6 B | 23.9 B | 24 B | 23.8 B | 25.8 B | 24.6 B | 24.9 B |
Cost of Revenue |
61.2 B | 58.9 B | 55.4 B | 59.1 B | 57 B | 54 B | 51.1 B | 55.3 B | 52.9 B | 50 B | 48.1 B | 57.4 B | 54.7 B | 53.5 B | 51.5 B | 51.7 B | 50.4 B | 49.3 B | 45.5 B | 46.4 B | 45 B | 43.5 B | 40.9 B | 42.5 B | 40.9 B | 40.2 B | 40.3 B | 42.1 B | 40.4 B | 39 B | 37.2 B | 40.6 B | 39.5 B | 38.9 B | 37.5 B | 37.7 B | 39.1 B | 38.8 B | 37.9 B | - | 37.1 B | 36.7 B | 36.5 B | - | 32 B | 30.8 B | 30.2 B | - | 28.6 B | 28.3 B | 26.7 B | - | 25.9 B | 25.4 B | 25.2 B | - | 24.6 B | 25.3 B | 25.7 B | - | 21.5 B | 21.3 B | 21 B | - | 18.9 B | 19 B | 19 B | 19.8 B | 19.6 B | 19.8 B |
Gross Profit |
47.2 B | 47.2 B | 45 B | 46.6 B | 45.8 B | 44.9 B | 43.5 B | 42.4 B | 42.5 B | 41.2 B | 40.4 B | 36.4 B | 35.1 B | 35.4 B | 33.8 B | 32.1 B | 30.8 B | 31.3 B | 31.3 B | 30.2 B | 28.8 B | 29.1 B | 28.2 B | 27.1 B | 26.1 B | 25.1 B | 26.4 B | 24.8 B | 24.1 B | 24.2 B | 24.2 B | 13.9 B | 7.33 B | 7.2 B | 6.86 B | 7.9 B | 7.12 B | 6.93 B | 6.57 B | 7.61 B | 7.49 B | 7.02 B | 6.74 B | 7.3 B | 6.66 B | 6.4 B | 6.16 B | 6.63 B | 6.47 B | 6.32 B | 5.94 B | 6.34 B | 6.03 B | 5.84 B | 5.58 B | 6.29 B | 5.65 B | 5.45 B | 5.11 B | 5.56 B | 5.18 B | 5.09 B | 4.74 B | 5.45 B | 5.02 B | 5.02 B | 4.75 B | 5.57 B | 5.01 B | 5.05 B |
Operating Income |
3.57 B | 4.7 B | 4.68 B | 2.11 B | -3.21 B | 2.38 B | 3.37 B | 2.37 B | 832 M | 3.04 B | 2.27 B | 3.37 B | 3.69 B | 3.23 B | 3.45 B | 3.66 B | -3.92 B | 4.67 B | 3.54 B | 2.35 B | 3.06 B | 4.33 B | 3.58 B | 2.52 B | 3.25 B | 4.68 B | 3.46 B | 3.04 B | 2.93 B | 3.33 B | 2.69 B | 824 M | 2.57 B | -1.37 B | 2 B | 3.11 B | 2.5 B | 2.12 B | 1.8 B | 3 B | 2.82 B | 2.36 B | 2.18 B | 2.73 B | 2.33 B | 2.26 B | 2.13 B | 2.32 B | 2.25 B | 2.21 B | 2.02 B | 2.22 B | 2.15 B | 1.97 B | 1.69 B | 2.3 B | 1.81 B | 1.7 B | 1.4 B | 1.96 B | 1.58 B | 1.48 B | 1.3 B | 1.76 B | 1.48 B | 1.5 B | 1.41 B | 1.9 B | 1.57 B | 1.6 B |
Interest Expense |
30 M | 31 M | 32 M | 29 M | 26 M | 29 M | 28 M | 25 M | 25 M | 24 M | 25 M | 22 M | 22 M | 22 M | 22 M | 43 M | 41 M | 43 M | 42 M | 38 M | 49 M | 45 M | 50 M | -153 M | 54 M | 45 M | 54 M | -31 M | 31 M | 772 M | 782 M | 865 M | -453 M | 202 M | -42 M | 744 M | -245 M | -247 M | -252 M | - | 258 M | 284 M | 288 M | - | 268 M | 171 M | 137 M | - | 158 M | 161 M | 161 M | - | 125 M | 127 M | 127 M | - | 135 M | 132 M | 133 M | - | 156 M | 149 M | 135 M | - | 138 M | 136 M | -128 M | -132 M | -123 M | -128 M |
EBITDA |
3.99 B | 5.13 B | 5.12 B | 2.6 B | -2.71 B | 2.88 B | 3.87 B | 2.87 B | 1.34 B | 3.55 B | 2.78 B | 3.88 B | 4.2 B | 3.72 B | 3.85 B | 4.06 B | -3.46 B | 5.13 B | 4.01 B | 2.85 B | 3.62 B | 4.91 B | 4.16 B | 3.11 B | 3.84 B | 5.26 B | 4.04 B | 3.65 B | 3.54 B | 3.92 B | 3.31 B | 1.19 B | 2.79 B | -1.16 B | 2.21 B | 2.07 B | 3.12 B | 2.74 B | 2.42 B | 3 B | 4.67 B | 3.59 B | 2.8 B | 2.73 B | 3.84 B | 3.24 B | 2.62 B | 2.32 B | 3.69 B | 3.17 B | 2.5 B | 2.22 B | 3.57 B | 2.92 B | 2.2 B | 2.3 B | 3.11 B | 2.56 B | 1.82 B | 1.96 B | 2.76 B | 2.25 B | 1.68 B | 1.76 B | 2.58 B | 2.23 B | 1.77 B | 2.25 B | 2.6 B | 2.34 B |
Operating Expenses |
43.6 B | 42.5 B | 40.3 B | 44.5 B | 49 B | 42.5 B | 40.2 B | 40.1 B | 41.6 B | 38.2 B | 38.1 B | 33 B | 31.4 B | 32.2 B | 30.4 B | 28.5 B | 34.7 B | 9.17 B | 9.88 B | 27.9 B | 25.7 B | 8.87 B | 8.92 B | 24.6 B | 8.47 B | 8.67 B | 8.56 B | 8.65 B | 8.6 B | 8.04 B | 8.25 B | 6.61 B | 4.98 B | 4.87 B | 4.91 B | 4.6 B | 4.62 B | 4.81 B | 4.78 B | 4.61 B | 4.67 B | 4.66 B | 4.56 B | 4.57 B | 4.33 B | 4.14 B | 4.03 B | 4.31 B | 4.22 B | 4.12 B | 3.92 B | 4.12 B | 3.87 B | 3.87 B | 3.88 B | 4 B | 3.83 B | 3.74 B | 3.71 B | 3.6 B | 3.59 B | 3.6 B | 3.44 B | 3.69 B | 3.54 B | 3.52 B | 3.34 B | 3.66 B | 3.45 B | 3.45 B |
Quarterly performance
Select metrics to display
All numbers in USD currency
The income statement is one of the three key financial reports of a company CVS Health Corporation (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.
Reports on the profits and losses of other stocks in the Health care industry
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
Centene Corporation
CNC
|
$ 70.23 | 2.47 % | $ 34.6 B |  USA |
 |
Humana
HUM
|
$ 437.88 | 3.46 % | $ 52.7 B | USA |
 |
UnitedHealth Group Inc.
UNH
|
$ 405.09 | 1.88 % | $ 368 B | USA |
 |
Cigna Corporation
CI
|
$ 302.0 | 2.17 % | $ 79.6 B | USA |
 |
Triple-S Management Corporation
GTS
|
- | 0.28 % | $ 847 M | USA |
 |
NovoCure Limited
NVCR
|
$ 11.84 | -5.55 % | $ 1.32 B |  Jersey |
 |
Molina Healthcare
MOH
|
$ 204.87 | 0.75 % | $ 10.8 B | USA |
 |
Magellan Health, Inc.
MGLN
|
- | -0.19 % | $ 2.49 B | USA |
 |
Anthem
ANTM
|
- | -2.32 % | $ 107 B | USA |